{
  "id": "58bac5e822d3005309000012",
  "type": "summary",
  "question": "How are triple negative gliomas characterized?",
  "ideal_answer": "of these markers - 1p/19q deletions , mgmt methylation status , and mutations in the idh1 gene - are so potent that a new brain tumor subtype , the \"triple negative\" glioma (1p/19q intact , mgmt unmethylated , idh1 non-mutated) has entered common parlance . ",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/23288644",
    "http://www.ncbi.nlm.nih.gov/pubmed/22890969",
    "http://www.ncbi.nlm.nih.gov/pubmed/26989023",
    "http://www.ncbi.nlm.nih.gov/pubmed/23831947",
    "http://www.ncbi.nlm.nih.gov/pubmed/26061753",
    "http://www.ncbi.nlm.nih.gov/pubmed/21889777"
  ],
  "snippets": [
    {
      "text": "According to IDH, TP53, and 1p19q status, four major subtypes of LGG are recorded: IDH+/p53-/1p19q-, IDH+/p53+/1p19q-, IDH+/p53-/1p19q+ and triple negative, this last subgroup having the worst prognosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21889777",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22890969",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Among 615 grade II or III gliomas, 29% had all three alterations (i.e., were triple-positive), 5% had TERT and IDH mutations, 45% had only IDH mutations, 7% were triple-negative, and 10% had only TERT mutations; 5% had other combinations. Among 472 grade IV gliomas, less than 1% were triple-positive, 2% had TERT and IDH mutations, 7% had only IDH mutations, 17% were triple-negative, and 74% had only TERT mutations",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26061753",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Three of these markers - 1p/19q deletions, MGMT methylation status, and mutations in the IDH1 gene - are so potent that a new brain tumor subtype, the \"triple negative\" glioma (1p/19q intact, MGMT unmethylated, IDH1 non-mutated) has entered common parlance",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23288644",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Few data are available in the literature regarding the relationship between IDH mutations and HIF expression in low-grade gliomas (LGGs), especially in a recently described aggressive molecular subtype: \"triple negative\" (IDH non mutated, 1p 19q non codeleted, p53 expression negative) gliomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26989023",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22890969",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Three of these markers - 1p/19q deletions, MGMT methylation status, and mutations in the IDH1 gene - are so potent that a new brain tumor subtype, the \"triple negative\" glioma (1p/19q intact, MGMT unmethylated, IDH1 non-mutated) has entered common parlance.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23288644",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22890969",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22890969",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Few data are available in the literature regarding the relationship between IDH mutations and HIF expression in low-grade gliomas (LGGs), especially in a recently described aggressive molecular subtype: \"triple negative\" (IDH non mutated, 1p 19q non codeleted, p53 expression negative) gliomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26989023",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}